Familial Hypercholesterolemia and Your LDLR Gene Result: What the Research Actually Says

Familial Hypercholesterolemia and Your LDLR Gene Result: What the Research Actually Says

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Familial hypercholesterolemia (FH) is common — roughly 1 in 250 adults — and its danger comes almost entirely from being missed, not from being untreatable. Research is clear: untreated FH raises the lifetime risk of early heart disease because LDL cholesterol has been high since birth, but early, sustained LDL lowering strongly bends that risk back toward normal. A high LDL number or a gene flag is an entry ticket to treatment, not a sentence of an early heart attack.

What you’ll learn

• Why “inherited high cholesterol” means a treatable trajectory, not a fixed fate.
• Why a negative 23andMe result does not rule FH out — and what actually diagnoses it.
• The difference between your genotype, your LDL number, and a variant of uncertain meaning.
• What modern treatment can do, and what discrimination laws (GINA, ACA, Canada’s GNDA) protect.

This article aggregates published research to replace fear with facts. It does not replace individual medical advice from your own physician or a genetic counselor.

The Gene Behind the Report: LDLR and Why “Autosomal Dominant” Matters

Familial hypercholesterolemia is most often caused by a pathogenic variant in the LDLR gene on chromosome 19. This gene builds the LDL receptor, the “vacuum” that pulls LDL cholesterol out of your blood. When one copy is faulty, fewer receptors work, and LDL rises from birth. Less often, FH involves the APOB or PCSK9 genes.

FH follows an autosomal-dominant pattern, meaning a single altered copy is enough to cause markedly high LDL. Think of it like a paired brake system where one broken pedal is enough to slow clearance. Because only one copy is needed, each child of an affected parent has about a 50% chance of inheriting it, and FH does not “skip generations”.

Genotype also sorts people into two very different groups:

Form	What it means
Heterozygous FH (one affected copy)	Common — about 1 in 250 — and highly treatable
Homozygous FH (two affected copies)	Rare and far more severe, with very high LDL from early childhood

One caveat matters. Consumer tests like 23andMe report only a limited set of specific variants and do not sequence the whole LDLR, APOB, or PCSK9 genes. More than 2,000 different LDLR variants exist, so a “variant not detected” result does not clear you. If a report raises questions, a primary care physician or a genetic counselor (find one via NSGC.org) can help you read it correctly.

Section recap: A faulty LDLR gene raises LDL from birth, and one copy is enough because FH is autosomal dominant. Consumer tests screen only selected variants, so they cannot rule FH out.

How Common FH Really Is — and Why It Is So Widely Missed

Many people picture inherited high cholesterol as rare. Research says the opposite. The CDC classifies FH as a “Tier 1” genomic condition, meaning the evidence is strong enough to act on, on par with certain hereditary cancers. CDC materials estimate FH affects roughly 1 in 250 people in the US.

Yet the large majority go unrecognized. A global call to action from the FH Foundation reports that only about 10% of people with FH are diagnosed and adequately treated. In plain terms, for every 10 people who have it, about 9 do not know. The European Atherosclerosis Society reached the same conclusion, calling FH “underdiagnosed and undertreated” and noting under 1% are diagnosed in many countries.

Here is why this happens in real life. A high LDL is often treated as a lifestyle issue, so a hereditary work-up is never triggered, and families with clustering early heart disease go unrecognized for a generation. It is like a smoke alarm nobody installed. The reassuring flip side: “common and treatable but chronically missed” — not rarity — is what makes FH dangerous, which is exactly why a personal or family finding is worth acting on. A primary care physician or genetic counselor can start that work-up.

Section recap: FH is common (about 1 in 250) but only around 1 in 10 affected people are diagnosed and treated. Being missed, not being untreatable, is the core danger.

The Real Risk, in Honest Numbers: A Trajectory You Can Change

Here is the fear most readers carry: does FH mean an early heart attack like a parent’s? Research gives an honest, two-part answer. Untreated heterozygous FH does substantially raise the lifetime risk of premature coronary artery disease, because LDL has been elevated since birth — a lifelong “cholesterol-years” burden.

But that risk is driven by LDL exposure over time, and exposure is strongly modifiable. The American Heart Association’s FH statement is explicit: early, sustained LDL lowering substantially reduces the risk that lifelong high LDL creates. Think of it like sun exposure — total lifetime dose matters, and cutting it early changes the outcome. FH means a real, elevated, but treatable trajectory, not a fixed date.

Registry data show why acting matters. In the US CASCADE-FH registry of 1,295 adults with heterozygous FH, the median untreated LDL was 239 mg/dL, and 36% already had coronary heart disease — a real burden tied to years of undertreatment. Yet even on treatment, the median LDL was still 141 mg/dL, showing many people never reach goal. The lesson is not despair; it is that reaching an effective LDL goal early is the lever. Your personal numbers and family history belong in a conversation with a clinician, not a search bar.

Section recap: Untreated FH raises lifetime heart-disease risk through lifelong LDL exposure, but early, sustained LDL lowering bends that curve back toward normal. Reaching an LDL goal early is the decisive step — plan it with a clinician.

Testing: What a Gene Report Says vs. How FH Is Actually Diagnosed

A DNA report and a diagnosis are not the same thing. A consumer test can flag a known FH variant, but it screens only selected changes and cannot rule FH out. Crucially, FH is diagnosed clinically, from your LDL number plus your personal and family history — not from a gene report alone.

Clinicians use validated scoring criteria to make the call:

• Look at the untreated LDL number. In adults, an untreated LDL around 190 mg/dL or higher raises strong suspicion; in children, about 160 mg/dL or higher.
• Add personal and family history. Premature heart disease in close relatives weighs heavily in scores such as the Dutch Lipid Clinic Network (DLCN), Simon Broome, and US MEDPED criteria.
• Confirm genetically when useful. A clinician or a lab such as Invitae or Color can sequence LDLR, APOB, and PCSK9 — the genes behind FH — to confirm the diagnosis and enable family testing.

Think of the gene report as a “check engine” light and the lipid panel as the mechanic looking under the hood. A consumer result — positive or negative — should prompt a clinical lipid work-up before you draw conclusions. And because up to 30–40% of clinically definite FH cases have no identifiable variant on current panels, a normal genetic test does not exclude FH when the LDL phenotype is present. GeneReviews states the same point plainly: a negative or uninformative genetic test does not rule FH out when the LDL phenotype and family history are present. Ask your primary care physician for a fasting lipid panel, and consider a genetic counselor via NSGC.org.

Section recap: FH is diagnosed clinically from a high LDL plus family history using DLCN, Simon Broome, or MEDPED criteria; a negative DTC or gene test does not rule it out. Confirm with a clinical lipid work-up.

Reading Your Result: Genotype, Phenotype, and the “Uncertain” Middle

Much online content blurs three separate ideas into one scary label. Separating them defuses most of the fear. Expert guidance is clear that a clinical FH diagnosis can rest on phenotype alone, and that genetics adds value without being required.

• Genotype. A confirmed pathogenic LDLR, APOB, or PCSK9 variant confirms FH and predicts lifelong high LDL.
• Phenotype. A persistently very high LDL plus a supportive family history can establish a clinical FH diagnosis even without an identified variant, because current panels miss some causes.
• Variant of uncertain significance (VUS). Sometimes a DNA change is found but its effect is not established — a VUS should not be over-interpreted.

A helpful analogy: the lipid panel and family history are the compass, and a gene report is a useful map that is neither necessary nor sufficient on its own. This is why it matters to confirm whether a flagged variant is truly pathogenic before acting on it. Only a clinician can integrate genotype, LDL number, and history into a diagnosis and plan. A genetic counselor via NSGC.org can explain a VUS in plain terms.

Section recap: Genotype, LDL phenotype, and a VUS are three different things; the LDL number plus family history is the pivot, not the gene report alone. A clinician integrates them.

The Good News: A Mature, Effective Treatment Toolkit

Here is what sets FH apart from many genetic risks: it has a mature, guideline-endorsed toolkit for lowering LDL, the single lever that reduces cardiovascular risk. High-intensity statins are the first-line backbone, with ezetimibe as a common add-on, and the AHA statement frames early, sustained LDL lowering as the goal.

When statins alone are not enough, the PCSK9 pathway changed the picture. Two monoclonal antibodies — evolocumab (Repatha) and alirocumab (Praluent) — were both FDA-approved in 2015 (alirocumab on July 24 and evolocumab on August 27) and are also authorized by Health Canada. A newer small-interfering-RNA agent, inclisiran (Leqvio), was FDA-approved on December 22, 2021, and is likewise authorized by Health Canada; after initial doses it is given as a twice-yearly injection.

The outcomes evidence is strong. In the FOURIER trial of 27,564 patients on statins, adding evolocumab lowered LDL by about 59% (from a median of 92 to 30 mg/dL) and significantly reduced cardiovascular events. The ORION-10 and ORION-11 trials showed inclisiran cut LDL by roughly 50% with twice-yearly dosing. Bempedoic acid is another oral option, and lipoprotein apheresis (a blood-filtering procedure) is reserved for severe or homozygous cases.

Two honest caveats. First, PCSK9 agents and inclisiran are typically added to statins, not replacements, to reach an individualized LDL goal. Second, no gene-directed disease-modifying therapy is standard of care for heterozygous FH as of 2026; management centers on early, sustained LDL lowering. Treat every option here as something to discuss with a clinician, not a self-directed choice.

Section recap: Statins are the backbone, with ezetimibe, PCSK9 inhibitors (evolocumab and alirocumab, FDA 2015; both Health Canada-authorized), and inclisiran (FDA 2021) as add-ons. Reaching an LDL goal is a plan to build with a clinician.

What This Means for Your Children and Relatives

Because FH is autosomal dominant, the family math is simple and worth acting on. Each first-degree relative — parents, siblings, and children — of a person with FH has about a 50% chance of also having it. That is why FH is the textbook case for cascade screening: systematically checking relatives once one person is identified, an approach the FH Foundation strongly endorses.

The evidence and major organizations strongly endorse this. The AHA statement recommends cascade screening of first-degree relatives and screening of children, because FH can and should be detected early, when treatment is most protective. Genetic testing is especially useful here: when a familial variant is known, relatives can be tested for that exact change. Think of it as checking the houses next door once a leak is found on the street.

For the reader whose father and brother are affected, the practical message is direct: her own children are candidates for early cholesterol checks, since FH can be identified and treated in childhood. Rather than alarming relatives on your own, coordinate family testing through a clinician and consider a board-certified genetic counselor via the NSGC.org find-a-counselor tool (which links to ABGC-certified counselors).

Section recap: Each first-degree relative has about a 50% chance of FH, so cascade screening — including early cholesterol checks in children — is the family-protecting payoff. Coordinate it through a clinician or genetic counselor.

Insurance, Employment, and Telling Your Family: The Honest Picture

Insurance and disclosure anxiety deserve a straight answer. In the United States, the Genetic Information Nondiscrimination Act of 2008 (GINA) prohibits discrimination based on genetic information in health insurance (Title I) and employment (Title II, enforced by the EEOC). The Affordable Care Act (ACA) separately bars health insurers from denying or pricing coverage based on pre-existing conditions.

But there is a real gap worth understanding:

GINA / ACA cover	GINA does NOT cover
Health insurance (GINA Title I)	Life insurance
Employment (GINA Title II, EEOC-enforced)	Disability insurance
(ACA bars pre-existing-condition pricing)	Long-term-care insurance

There is also a subtle point in your favor. Because FH is frequently diagnosed from cholesterol numbers and family history alone, a clinical FH diagnosis can exist entirely independent of any gene test. In Canada, protection is broader: the Genetic Non-Discrimination Act of 2017 prohibits requiring or disclosing a genetic test result to obtain goods, services, or a contract (including insurance), and the Supreme Court of Canada upheld it in 2020. Provincial health plans (such as OHIP and RAMQ) cover care regardless.

The emotional weight of a “lifelong high-risk” label is real. It helps to keep the framing throughout this article: identifying FH is a manageable, treatable heads-up that protects the whole family, not a sentence of early heart disease. Whether and how to tell relatives is a personal, counseled decision, best made with a genetic counselor via NSGC.org and your family doctor.

Section recap: GINA and the ACA protect health insurance and employment but not life, disability, or long-term-care coverage; Canada’s GNDA is broader, and FH is often diagnosed without a gene test. A counselor can help you plan disclosure.

Frequently Asked Questions

Will I get an early heart attack if I have FH? Not as a fixed fate. Untreated FH raises lifetime risk because LDL has been high since birth, but the AHA statement shows early, sustained LDL lowering strongly reduces that risk. Reaching an LDL goal early, with a clinician, is the decisive step.

Will my children inherit it? FH is autosomal dominant, so each child has about a 50% chance. Children of an affected parent should have early cholesterol screening, since FH can be identified and treated in childhood. The CDC likewise frames early detection and treatment as the way to prevent premature heart disease from lifelong high LDL.

Will this affect my health or life insurance? GINA and the ACA protect your health insurance and employment in the US. However, GINA does not cover life, disability, or long-term-care insurance; Canada’s GNDA is broader.

Can my employer find out and use it against me? GINA prohibits employment discrimination based on genetic information, enforced by the EEOC. This is a specific protection, but a genetic counselor or attorney can address your particular situation.

Should I get a second opinion or confirmatory testing? Yes. A consumer result screens only selected variants and does not diagnose FH; a normal test does not rule it out. Guidelines diagnose FH clinically from a lipid panel plus family history using validated criteria.

Summary

An “FH” flag or a stubbornly high LDL describes a treatable inherited condition, not a verdict of early heart disease. Research is consistent: FH is common (about 1 in 250) yet mostly undiagnosed, and its danger lies in being missed. Untreated FH raises lifetime heart-disease risk through lifelong LDL exposure, but early, sustained LDL lowering bends that trajectory back toward normal. The path forward is concrete: FH is diagnosed clinically from your LDL number plus family history, so a negative gene test does not clear you; the treatment ladder — statins, ezetimibe, PCSK9 inhibitors, and inclisiran — can reach goals unattainable a generation ago; and cascade screening protects the whole family, including children. Legal protections cover your health coverage and job, with specific gaps worth knowing. This is one of the most detectable and treatable inherited cardiovascular risks there is. Use it as a reason to act, and take the next step with a clinician or genetic counselor. This article is educational and does not replace individual medical advice.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Gidding SS, et al. (2015). The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000297
2. Nordestgaard BG, et al. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population — European Atherosclerosis Society Consensus Statement. European Heart Journal. https://academic.oup.com/eurheartj/article/34/45/3478/435928
3. Cuchel M, et al. (2014). Homozygous familial hypercholesterolaemia — European Atherosclerosis Society Consensus Panel position paper. European Heart Journal. https://academic.oup.com/eurheartj/article/35/32/2146/447773
4. Sabatine MS, et al. (2017). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1615664
5. Ray KK, et al. (2020). Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (ORION-10 and ORION-11). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1912387
6. deGoma EM, O’Brien EC, et al. (2016). Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States (CASCADE-FH Registry). Circulation: Cardiovascular Genetics. https://www.ahajournals.org/doi/10.1161/CIRCGENETICS.116.001381
7. MedlinePlus Genetics, National Library of Medicine / NIH. Familial hypercholesterolemia and the LDLR gene. https://medlineplus.gov/genetics/condition/familial-hypercholesterolemia/
8. Centers for Disease Control and Prevention (CDC), Office of Genomics and Precision Public Health. Familial Hypercholesterolemia — Tier 1 Genomics. https://blogs.cdc.gov/genomics/2021/01/25/how-common-is-fh/
9. Youngblom E, et al. Familial Hypercholesterolemia — GeneReviews, NCBI Bookshelf / National Library of Medicine (NIH). https://www.ncbi.nlm.nih.gov/books/NBK174884/
10. U.S. FDA / Health Canada. Evolocumab (Repatha) and alirocumab (Praluent) — approved PCSK9-inhibitor therapies. https://www.drugs.com/history/repatha.html
11. U.S. FDA / Health Canada. Inclisiran (Leqvio) — approved small-interfering-RNA PCSK9-synthesis inhibitor. https://www.drugs.com/history/leqvio.html
12. Sturm AC, et al. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. Journal of the American College of Cardiology. https://www.jacc.org/doi/10.1016/j.jacc.2018.05.044
13. Wilemon KA, et al. (2020). Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action (FH Foundation). JAMA Cardiology. https://pubmed.ncbi.nlm.nih.gov/31895433/
14. NHGRI/NIH, U.S. EEOC, and Government of Canada. Genetic Information Nondiscrimination Act (GINA, 2008), the Affordable Care Act, and Canada’s Genetic Non-Discrimination Act (2017). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination

Tier distribution: 14 sources total — tier 1 (A) = 8, tier 2 (B) = 6, including NIH (MedlinePlus, GeneReviews), CDC, FDA/Health Canada regulatory records, and clinical guidance from the American Heart Association, the European Atherosclerosis Society, and the JACC Scientific Expert Panel. Note: PCSK9 inhibitors (evolocumab and alirocumab, FDA-approved 2015) and inclisiran (FDA-approved 2021) are all authorized by Health Canada as add-ons to statins; no gene-directed disease-modifying therapy is standard of care for heterozygous FH as of 2026.

---

Last updated: 2026-07-14

Author: Yu Mizuno (Editor-in-Chief, non-physician), GeneLumen editorial team. This article aggregates 14 sources from peer-reviewed medical literature and public health agencies (tier 1=8 / tier 2=6), including NIH, CDC, Health Canada, and clinical guidance from the American Heart Association, the European Atherosclerosis Society, and the American College of Cardiology (JACC Scientific Expert Panel).

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-metabolic-hematologic-genetic/ldlr-familial-hypercholesterolemia-genetic-risk-ldl-exposure